Retatrutide Research

Retatrutide Clinical Trial Timeline: Phase 1 to TRIUMPH

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library1 min readLast reviewed 2026-08-224 cited sources

The short answer

Retatrutide's clinical timeline began with Phase 1 first-in-human dosing around 2020 and Phase 2 results in the New England Journal of Medicine in 2023. The Phase 3 TRIUMPH programme launched in 2023 and reported across December 2025 to July 2026, with all pivotal trials meeting their primary endpoints. An FDA filing has been signalled for Q1 2027.

Key facts

Phase 1
~2020 (NCT04143802)
Phase 2
Published NEJM 2023 (Jastreboff et al.)
Phase 3 launch
2023 (TRIUMPH programme)
First Phase 3 readout
TRIUMPH-4, December 2025
Pivotal readout
TRIUMPH-1, 21 May 2026
Comorbid populations
TRIUMPH-2 and -3, July 2026
Signalled FDA filing
Q1 2027

What is the TRIUMPH programme?

TRIUMPH is Eli Lilly's Phase 3 development umbrella for retatrutide, comprising multiple trials across obesity, type 2 diabetes and cardiovascular populations, with more than 5,800 participants enrolled in total. Registrations are listed on ClinicalTrials.gov.

How the Phase 3 readouts landed

TRIUMPH-4 reported first in December 2025. The pivotal obesity study, TRIUMPH-1, reported topline results on 21 May 2026 across 2,339 randomised adults. TRIUMPH-2, in obesity with type 2 diabetes, and TRIUMPH-3, in severe obesity with established cardiovascular disease, both reported in July 2026 and both met their primary endpoints.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What comes next

Further Phase 3 readouts were expected across 2026, including maintenance-dosing studies examining what happens when the dose is reduced or withdrawn. Lilly has signalled an FDA Biologics License Application in the first quarter of 2027; regulatory review commonly adds a year or more, and retatrutide remains investigational throughout.

Quick reference

StageDateOutcome
Phase 12020First-in-human, single/multiple ascending doses
Phase 22022-2023Obesity + T2D; NEJM publication 2023
TRIUMPH-4Dec 2025First Phase 3 readout
TRIUMPH-121 May 202628.3% mean reduction at 80 wks (12 mg)
TRIUMPH-2 / -3July 2026Both met primary endpoints
FDA filingQ1 2027 (planned)Not yet submitted

Frequently asked questions

How long are Phase 3 trials?

TRIUMPH trials run multi-year. TRIUMPH-1 had its primary analysis at 80 weeks with a 104-week extension.

Is the Phase 3 programme finished?

The pivotal trials have reported, but the programme continues. Maintenance-dosing studies were still outstanding.

When could retatrutide reach the market?

No date exists. A filing was signalled for Q1 2027, and review typically takes a year or more with no guaranteed outcome.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.